AbbVie, Inc. (NYSE:ABBV) flagship product, Humira sales decelerated in the first three quarters of 2019 given the launch of... ByZacks Investment Research • Feb 04, 2020 AbbVie (ABBV ...

Monster Hunter Wilds is the big success story of February, according to Circana's charts, though overall industry sales are still in decline.

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly ...

Not only that, the album is also making a buzz on the Billboard as based on recent reports, it has ranked at the no. 1 on both its Top Album Sales chart and Top Current Album Sales chart ...

AbbVie’s immunology portfolio, particularly Skyrizi and Rinvoq, has been instrumental in offsetting the decline in Humira sales. These two drugs have consistently outperformed expectations, with ...

SB19’s comeback started on a strong note as “Dam” debuted at the top spot of Billboard’s World Digital Song Sales chart, making them the first Filipino act to achieve this milestone.

Fatalities from drugs including fentanyl are down from a 2022 peak.

Sandoz reported a 9% growth in net sales of generics and biosimilars to ... Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS ...

Humira is starting to feel the effects of lower-cost biosimilar competition in some markets however, with sales falling for the first time in the second quarter of this year. The FDA approval for ...

Thanks to that massive sales surge, GNX hits No. 1 on the Top Album Sales chart for the first time. This frame marks the project's second on the list, as it reappears from out of nowhere in first ...